PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MRNA vs. NVAX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Performance

MRNA vs. NVAX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and Novavax, Inc. (NVAX). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%40.00%JuneJulyAugustSeptemberOctoberNovember
-72.70%
-47.49%
MRNA
NVAX

Returns By Period

In the year-to-date period, MRNA achieves a -61.29% return, which is significantly lower than NVAX's 61.77% return.


MRNA

YTD

-61.29%

1M

-28.84%

6M

-71.03%

1Y

-49.63%

5Y (annualized)

14.78%

10Y (annualized)

N/A

NVAX

YTD

61.77%

1M

-23.72%

6M

-47.50%

1Y

35.51%

5Y (annualized)

16.10%

10Y (annualized)

-22.76%

Fundamentals


MRNANVAX
Market Cap$16.73B$1.35B
EPS-$5.81-$2.62
PEG Ratio0.000.00
Total Revenue (TTM)$5.08B$800.68M
Gross Profit (TTM)$3.35B$566.95M
EBITDA (TTM)-$2.41B-$126.11M

Key characteristics


MRNANVAX
Sharpe Ratio-0.840.23
Sortino Ratio-1.191.75
Omega Ratio0.851.21
Calmar Ratio-0.540.34
Martin Ratio-1.391.03
Ulcer Index35.78%32.08%
Daily Std Dev59.17%142.67%
Max Drawdown-92.39%-98.82%
Current Drawdown-92.05%-97.57%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Correlation

-0.50.00.51.00.4

The correlation between MRNA and NVAX is 0.44, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Risk-Adjusted Performance

MRNA vs. NVAX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Novavax, Inc. (NVAX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MRNA, currently valued at -0.84, compared to the broader market-4.00-2.000.002.004.00-0.840.23
The chart of Sortino ratio for MRNA, currently valued at -1.19, compared to the broader market-4.00-2.000.002.004.00-1.191.75
The chart of Omega ratio for MRNA, currently valued at 0.85, compared to the broader market0.501.001.502.000.851.21
The chart of Calmar ratio for MRNA, currently valued at -0.54, compared to the broader market0.002.004.006.00-0.540.34
The chart of Martin ratio for MRNA, currently valued at -1.39, compared to the broader market0.0010.0020.0030.00-1.391.03
MRNA
NVAX

The current MRNA Sharpe Ratio is -0.84, which is lower than the NVAX Sharpe Ratio of 0.23. The chart below compares the historical Sharpe Ratios of MRNA and NVAX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00JuneJulyAugustSeptemberOctoberNovember
-0.84
0.23
MRNA
NVAX

Dividends

MRNA vs. NVAX - Dividend Comparison

Neither MRNA nor NVAX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MRNA vs. NVAX - Drawdown Comparison

The maximum MRNA drawdown since its inception was -92.39%, smaller than the maximum NVAX drawdown of -98.82%. Use the drawdown chart below to compare losses from any high point for MRNA and NVAX. For additional features, visit the drawdowns tool.


-100.00%-95.00%-90.00%-85.00%-80.00%-75.00%-70.00%-65.00%JuneJulyAugustSeptemberOctoberNovember
-92.05%
-97.57%
MRNA
NVAX

Volatility

MRNA vs. NVAX - Volatility Comparison

The current volatility for Moderna, Inc. (MRNA) is 15.79%, while Novavax, Inc. (NVAX) has a volatility of 17.20%. This indicates that MRNA experiences smaller price fluctuations and is considered to be less risky than NVAX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%JuneJulyAugustSeptemberOctoberNovember
15.79%
17.20%
MRNA
NVAX

Financials

MRNA vs. NVAX - Financials Comparison

This section allows you to compare key financial metrics between Moderna, Inc. and Novavax, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items